CN100408682C - 具有数目减少的vntr重复单位的muc-1抗原 - Google Patents

具有数目减少的vntr重复单位的muc-1抗原 Download PDF

Info

Publication number
CN100408682C
CN100408682C CNB038171988A CN03817198A CN100408682C CN 100408682 C CN100408682 C CN 100408682C CN B038171988 A CNB038171988 A CN B038171988A CN 03817198 A CN03817198 A CN 03817198A CN 100408682 C CN100408682 C CN 100408682C
Authority
CN
China
Prior art keywords
muc
cells
vntr
plasmid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038171988A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668746A (zh
Inventor
N·博登
J·H·埃利斯
P·A·汉布林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1668746A publication Critical patent/CN1668746A/zh
Application granted granted Critical
Publication of CN100408682C publication Critical patent/CN100408682C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB038171988A 2002-05-24 2003-05-23 具有数目减少的vntr重复单位的muc-1抗原 Expired - Fee Related CN100408682C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0212046.7 2002-05-24
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines

Publications (2)

Publication Number Publication Date
CN1668746A CN1668746A (zh) 2005-09-14
CN100408682C true CN100408682C (zh) 2008-08-06

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038171988A Expired - Fee Related CN100408682C (zh) 2002-05-24 2003-05-23 具有数目减少的vntr重复单位的muc-1抗原

Country Status (20)

Country Link
US (1) US20060251665A1 (enExample)
EP (1) EP1527177A2 (enExample)
JP (1) JP2005526520A (enExample)
KR (1) KR20050004211A (enExample)
CN (1) CN100408682C (enExample)
AR (1) AR039846A1 (enExample)
AU (1) AU2003240729B2 (enExample)
BR (1) BR0311211A (enExample)
CA (1) CA2485816A1 (enExample)
GB (1) GB0212046D0 (enExample)
IL (1) IL165156A0 (enExample)
IS (1) IS7526A (enExample)
MX (1) MXPA04011527A (enExample)
NO (1) NO20044947L (enExample)
NZ (1) NZ536668A (enExample)
PL (1) PL374569A1 (enExample)
RU (1) RU2303069C2 (enExample)
TW (1) TW200407426A (enExample)
WO (1) WO2003100060A2 (enExample)
ZA (1) ZA200409445B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
ES2476990T3 (es) * 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
JP5285855B2 (ja) * 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
KR20140023903A (ko) * 2011-02-24 2014-02-27 온코타이레온, 인코포레이티드 항원보강제를 갖는 muc1 기초 당지질펩티드 백신
SG11201805621SA (en) * 2016-01-19 2018-08-30 Pfizer Cancer vaccines
US11052139B2 (en) 2016-09-28 2021-07-06 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046228A2 (en) * 1999-12-22 2001-06-28 Glaxo Group Limited Nucleic acid vaccination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK70598A3 (en) * 1995-11-30 1999-04-13 Univ Texas Methods and compositions for the diagnosis and treatment of cancer
AU727308B2 (en) * 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
WO2002062319A2 (en) * 2001-01-19 2002-08-15 Corixa Corporation Microsphere delivery of mucin peptides
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046228A2 (en) * 1999-12-22 2001-06-28 Glaxo Group Limited Nucleic acid vaccination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Breast Cancer in Mice: Effect of Murine Muc-1 Immunizationon Tumor Incidence in C3H/HeOuj Mice. Xing Peii Xiang et al.Journal of Immunotherapy,Vol.24 No.1. 2001 *
Therapeutic antitumor response after immunization with anadmixture of recombinant vaccinia viruses expressing amodified MUC1 gene and the murine T-cell costimulatorymolecule B7. Akagi J et al.Journal of Immunotherapy,Vol.20 No.1. 1997 *

Also Published As

Publication number Publication date
IS7526A (is) 2004-11-11
CN1668746A (zh) 2005-09-14
NO20044947D0 (no) 2004-11-12
MXPA04011527A (es) 2005-09-30
RU2303069C2 (ru) 2007-07-20
JP2005526520A (ja) 2005-09-08
KR20050004211A (ko) 2005-01-12
PL374569A1 (en) 2005-10-31
RU2004134331A (ru) 2005-08-27
US20060251665A1 (en) 2006-11-09
NO20044947L (no) 2005-12-16
EP1527177A2 (en) 2005-05-04
TW200407426A (en) 2004-05-16
NZ536668A (en) 2007-01-26
CA2485816A1 (en) 2003-12-04
IL165156A0 (en) 2005-12-18
WO2003100060A3 (en) 2004-02-19
AU2003240729A1 (en) 2003-12-12
AR039846A1 (es) 2005-03-02
GB0212046D0 (en) 2002-07-03
AU2003240729B2 (en) 2007-12-20
ZA200409445B (en) 2006-02-22
WO2003100060A2 (en) 2003-12-04
BR0311211A (pt) 2005-03-01

Similar Documents

Publication Publication Date Title
AU2006299106A1 (en) Compositions and methods for treating tumors presenting survivin antigens
CN100408682C (zh) 具有数目减少的vntr重复单位的muc-1抗原
WO2019101062A9 (zh) 重组疫苗及其应用
JP2002528519A (ja) 抗腫瘍効果を有する、抗原性タンパク質をコードしているｄｎａを含む医薬組成物
CN100393878C (zh) 疫苗
EP1240317B1 (en) Nucleic acid vaccination
US20070042047A1 (en) Vaccines
US20060062798A1 (en) Vaccines
US20060147458A1 (en) Vaccines
JP2021523185A (ja) アレルゲンを含む改善されたｌａｍｐ構築物
WO2024222886A1 (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080806

Termination date: 20100523